(Q33994104)

30 July 2017

1 reference

title

Economics and health-related quality of life in antiemetic therapy: recommendations for trial design (English)

1 reference

30 July 2017

Uyl-de Groot CA

1

1 reference

30 July 2017

Wait S

series ordinal

2

1 reference

30 July 2017

Buijt I

series ordinal

3

1 reference

30 July 2017

publication date

1 August 2000

1 reference

European Journal of Cancer

30 July 2017

published in

1 reference

30 July 2017

volume

36

1 reference

30 July 2017

issue

12

1 reference

30 July 2017

page(s)

1522-1535

1 reference

Pharmacoeconomic aspects in the treatment of curable and incurable cancer.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Control of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Comparative studies of various antiemetic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

5-HT3 receptor antagonists: differences and similarities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Ondansetron: a cost-effective advance in anti-emetic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Quality of life studies in chemotherapy-induced emesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Improved control of emesis and quality of life with ondansetron in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Quality of life consequences of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900132-5

7 January 2021

10.1016/S0959-8049(00)00132-5

Identifiers

DOI

1 reference

30 July 2017

1 reference